Roche trims out some pipeline fail­ures while flag­ging a PhI­II flop for Tecen­triq

Roche flagged a key set­back for its late-stage pipeline to­day, say­ing their IM­mo­tion010 kid­ney can­cer ad­ju­vant study of Tecen­triq has failed.

Roche phar­ma chief Bill An­der­son told an­a­lysts in the Q2 call to­day that the drug flopped on the pri­ma­ry end­point of dis­ease-free sur­vival, es­sen­tial­ly elim­i­nat­ing any up­side here for a fran­chise that earned $1.8 bil­lion in the first half of the year, up 11% over the same pe­ri­od in 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER